Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8186696 | 0.94 | PAK4 (0.42) | ROCK2CYP3A4CYP2C19SLC2A1PTGES | |
| SCHEMBL8186701 | 0.94 | PAK4 (0.42) | ROCK2CYP3A4CYP2C19SLC2A1PTGES | |
| SCHEMBL12263484 | 0.93 | ROCK2 (0.41) | ROCK2BACE1CYP3A4CYP2C19SLC2A1 | |
| SCHEMBL14477229 | 0.92 | ROCK2 (0.50) | ROCK2BACE1CYP3A4CYP2C19SLC2A1 | |
| SCHEMBL3157931 | 0.90 | ROCK2 (0.43) | ROCK2BACE1CYP3A4CYP2C19SLC2A1 | |
| SCHEMBL3157925 | 0.90 | ROCK2 (0.43) | ROCK2BACE1CYP3A4CYP2C19SLC2A1 | |
| SCHEMBL2567314 | 0.89 | ROCK2 (0.46) | ROCK2BACE1CYP3A4CYP2C19SLC2A1 | |
| SCHEMBL2567313 | 0.89 | ROCK2 (0.46) | ROCK2BACE1CYP3A4CYP2C19SLC2A1 | |
| SCHEMBL31094025 | 0.89 | ROCK2 (0.41) | ROCK2BACE1CYP3A4CYP2C19MAPT | |
| SCHEMBL436224 | 0.89 | ROCK2 (0.41) | ROCK2BACE1CYP3A4CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130004481-A1 | ANTICANCER THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130004481-A1 | ANTICANCER THERAPY | AURKA, AURKC, AURKB | ROCK2 62/4885BACE1 3523/4885CYP3A4 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.